Bristol Myers Squibb presents ESMO data and Bristol Myers Squibb stock trades at EUR 55.94

Published on 10/23/2026 at 10:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb will present 12 oral talks and nearly 60 disclosures at ESMO. Bristol Myers Squibb stock costs EUR 55.94 on October 23, 2026.

Pipeline plans and market context

Bristol Myers Squibb scheduled 12 oral presentations and nearly 60 disclosures for October 23, 2026.
Second-quarter 2026 revenue reached USD 12.97 billion, up 5.70 percent year over year.
Bristol Myers Squibb stock traded at EUR 55.94 at 10:30 a.m. CEST at Lang & Schwarz on October 23, 2026.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb stock traded at EUR 55.94 at Lang & Schwarz on October 23, 2026, as the drugmaker began presenting a broad oncology pipeline at ESMO. According to Bristol Myers Squibb on October 19, 2026, the company planned 12 oral presentations and nearly 60 disclosures for the October 23-27 congress in Madrid.

Three events shape the story

Bristol Myers Squibb reported second-quarter 2026 revenue of USD 12.97 billion and diluted earnings per share of USD 1.62, according to the company's financial data. Revenue increased 5.70 percent from the year-earlier quarter, while net income attributable to common shareholders reached USD 3.32 billion.

On September 22, 2026, Bristol Myers Squibb announced plans affecting 265 Princeton employees as part of a multiyear cost program targeting USD 2.00 billion in annual savings by the end of 2027, flcube reported. On October 19, 2026, the company announced the ESMO program, including Phase 3 studies of izalontamab brengitecan and Phase 2 data for pumitamig, according to the official release.

What does the pipeline showcase mean?

The numerical breadth of the program gives investors a concrete measure of the pipeline effort: nearly 60 disclosures cover emerging and established oncology approaches. The release identified late-breaking data for pumitamig, which is being developed with BioNTech, alongside izalontamab brengitecan studies sponsored by SystImmune's parent company.

The immediate test is clinical execution rather than presentation volume. The company is scheduled to report third-quarter 2026 results on October 29 before the market opens, with MarketBeat citing consensus estimates of USD 12.74 billion in revenue and USD 1.10 in earnings per share, MarketBeat reported on October 22, 2026.

Dates investors can track

The ESMO congress runs from October 23, 2026, through October 27, 2026, and the next quarterly report is scheduled for October 29, 2026. Those dates place the clinical disclosures before the next financial checkpoint.

Stock price and valuation context

Bristol Myers Squibb's primary listing is on the NYSE under ticker BMY. Its stock traded at USD 63.00 on October 22, 2026, while the market capitalization was USD 128.7 billion and the 52-week range was USD 42.52 to USD 68.64. The euro quotation at Lang & Schwarz therefore remains the clearest German-market reference for the current session.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.